Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2009

View Archived Issues

Amgen scientists describe new Smo receptor antagonists in recent patent

New BACE inhibitors reported in recent Boehringer Ingelheim patent

Gilead reports data on boosting activity of fixed-dose combination therapy with GS-9350

New histamine H3 receptor ligands reported in recent High Point patent

Dainippon Sumitomo Pharma scientists claim new renin inhibitors

Bristol-Myers Squibb reports new SERT inhibitors and/or NK1 receptor antagonists

Shionogi updates Q3 progress

New HCV NS3/NS4A inhibitors discovered at Gilead

BMS researchers design novel chemokine CCR1 antagonists

Roche presents bifunctional HIV entry inhibitor CD4-BFFI

PROVE2: Telaprevir improves efficacy of hepatitis C treatment

Biodistribution, toxicity of suicide gene adenovirus therapy studied in vivo

PRO-140 shows potent and prolonged antiviral activity in HIV-1 infected individuals

Novel HIV-1 antiretroviral agents inhibit RNase H activity of viral reverse transcriptase

BioAlliance seeks E.U. MAA for fast-dissolving ondansetron

arGentis receives E.U. orphan drug designation for ARG-201

Agenix progresses ThromboView to final development stage

Diamyd receives approval for follow-up study for its diabetes vaccine

GlaxoSmithKline and Mitsubishi Tanabe to co-promote Adoair in Japan

Vical receives milestone payment from AnGes for Allovectin-7 phase III trial

Shionogi presents positive top-line efficacy results from velneperit studies

NeuroSearch enters ion channel target development alliance with Lilly

Northwest reports data from phase I and phase I/II clinical trials of DCVax-Brain

Proteo reports results from clinical study of Elafin in ARDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...